MA45941A - Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation - Google Patents
Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisationInfo
- Publication number
- MA45941A MA45941A MA045941A MA45941A MA45941A MA 45941 A MA45941 A MA 45941A MA 045941 A MA045941 A MA 045941A MA 45941 A MA45941 A MA 45941A MA 45941 A MA45941 A MA 45941A
- Authority
- MA
- Morocco
- Prior art keywords
- agonist activity
- modified anti
- tnfr superfamily
- use procedures
- improved agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374347P | 2016-08-12 | 2016-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45941A true MA45941A (fr) | 2019-06-19 |
Family
ID=61158615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045941A MA45941A (fr) | 2016-08-12 | 2017-08-04 | Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180044430A1 (fr) |
| EP (1) | EP3497126A4 (fr) |
| JP (2) | JP7009448B2 (fr) |
| KR (1) | KR102554331B1 (fr) |
| CN (1) | CN109843916B (fr) |
| AU (2) | AU2017308734A1 (fr) |
| CA (1) | CA3033665A1 (fr) |
| IL (1) | IL264515A (fr) |
| MA (1) | MA45941A (fr) |
| SG (1) | SG11201900744SA (fr) |
| WO (1) | WO2018031400A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6367836B2 (ja) | 2013-02-07 | 2018-08-01 | ザ ジェネラル ホスピタル コーポレイション | T制御性細胞の増殖または枯渇方法 |
| DK3447075T3 (da) | 2015-05-15 | 2023-11-13 | Massachusetts Gen Hospital | Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien |
| WO2017040312A1 (fr) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Anticorps agonistes anti-récepteurs de type ii du facteur de nécrose tumorale |
| KR20250007678A (ko) | 2016-05-13 | 2025-01-14 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
| BR112019015900A2 (pt) * | 2017-02-10 | 2020-04-07 | Genmab B.V. | polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| CA3074317C (fr) * | 2017-08-25 | 2024-06-18 | Janssen Biotech, Inc. | Domaines de type iii de fibronectine liant fc.gamma.rii, leurs conjugues et molecules multispecifiques les comprenant |
| WO2020041361A1 (fr) * | 2018-08-20 | 2020-02-27 | The General Hospital Corporation | Polypeptides antagonistes de la superfamille des récepteurs au facteur de nécrose tumorale |
| US20210371537A1 (en) * | 2018-09-18 | 2021-12-02 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| EP3880711A4 (fr) | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Polypeptides agonistes de la superfamille des récepteurs au facteur de nécrose tumorale |
| RU2734432C1 (ru) * | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| WO2021063313A1 (fr) * | 2019-09-30 | 2021-04-08 | 深圳市菲鹏生物制药股份有限公司 | Variante fc ayant une fonction effectrice modifiée et protéine de fusion de celle-ci |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
| JP7702735B2 (ja) * | 2021-03-05 | 2025-07-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | 農作物の生産成績を予測する予測モデルの生成方法、生成装置、及び生成プログラム |
| WO2022228364A1 (fr) | 2021-04-25 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | Anticorps anti-masp2, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée |
| AR127743A1 (es) * | 2021-09-06 | 2024-02-28 | Genmab Bv | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0281604B1 (fr) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Molecules de liaison de chaines de polypeptide simples |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0590058B1 (fr) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | ANTICORP HUMANISE specifique pour heregulin |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
| WO2001083755A2 (fr) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| ES2295639T3 (es) | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
| AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| EP1660126A1 (fr) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| WO2006028936A2 (fr) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Molecules heteromultimeriques |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | Gitr結合分子およびその使用 |
| US20110123440A1 (en) * | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| JP5027804B2 (ja) | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス,インコーポレーテッド | ヒト化抗cd40抗体およびその使用方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| WO2007133822A1 (fr) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Anticorps anti-gitr destinés au traitement du cancer |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (fr) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| SI2242771T1 (sl) | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Vezane molekule k humanemu ox40 receptorju |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク,インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| IN2015DN02826A (fr) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| JP6002659B2 (ja) | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトcd27に結合する抗体およびその使用 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CA2804550C (fr) | 2010-07-09 | 2021-01-05 | Bionovion Holding B.V. | Anticorps agoniste de cd27 |
| LT2609118T (lt) | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| JP6038920B2 (ja) | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ox40抗体およびそれを使用する方法 |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| WO2014006217A1 (fr) * | 2012-07-06 | 2014-01-09 | Genmab B.V. | Protéine dimérique ayant des mutations triples |
| CA2888763A1 (fr) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anticorps anti-cd40 et procedes d'utilisation |
| MX387324B (es) | 2013-01-10 | 2025-03-18 | Genmab Bv | Variantes de regiones fc de igg1 de humano y usos de las mismas. |
| PT2970980T (pt) | 2013-03-15 | 2018-11-19 | Janssen Biotech Inc | Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes |
| RS57840B1 (sr) * | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
| KR20160019434A (ko) * | 2013-06-14 | 2016-02-19 | 바이엘 파마 악티엔게젤샤프트 | 항-tweakr 항체 및 그의 용도 |
| MA40871A (fr) * | 2014-10-29 | 2017-09-05 | Novartis Ag | Expression directe d'anticorps |
| PT3247728T (pt) * | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| MX2017012805A (es) | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| MX2018006333A (es) | 2015-12-01 | 2018-08-01 | Genmab Bv | Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. |
| CA3032820A1 (fr) * | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Polypeptides synthetiques et leurs utilisations |
-
2017
- 2017-08-04 CA CA3033665A patent/CA3033665A1/fr active Pending
- 2017-08-04 WO PCT/US2017/045466 patent/WO2018031400A1/fr not_active Ceased
- 2017-08-04 MA MA045941A patent/MA45941A/fr unknown
- 2017-08-04 EP EP17840053.7A patent/EP3497126A4/fr active Pending
- 2017-08-04 AU AU2017308734A patent/AU2017308734A1/en not_active Abandoned
- 2017-08-04 SG SG11201900744SA patent/SG11201900744SA/en unknown
- 2017-08-04 JP JP2019507248A patent/JP7009448B2/ja active Active
- 2017-08-04 KR KR1020197007003A patent/KR102554331B1/ko active Active
- 2017-08-04 US US15/668,895 patent/US20180044430A1/en not_active Abandoned
- 2017-08-04 CN CN201780063333.0A patent/CN109843916B/zh active Active
-
2019
- 2019-01-28 IL IL264515A patent/IL264515A/en unknown
-
2020
- 2020-04-06 US US16/840,830 patent/US11359029B2/en active Active
-
2021
- 2021-11-11 JP JP2021184366A patent/JP2022033769A/ja active Pending
-
2024
- 2024-09-03 AU AU2024219359A patent/AU2024219359A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109843916B (zh) | 2023-10-31 |
| JP7009448B2 (ja) | 2022-02-10 |
| JP2022033769A (ja) | 2022-03-02 |
| WO2018031400A1 (fr) | 2018-02-15 |
| US20180044430A1 (en) | 2018-02-15 |
| EP3497126A4 (fr) | 2020-04-08 |
| AU2024219359A1 (en) | 2024-09-26 |
| KR20190038629A (ko) | 2019-04-08 |
| CA3033665A1 (fr) | 2018-02-15 |
| KR102554331B1 (ko) | 2023-07-10 |
| AU2017308734A1 (en) | 2019-02-14 |
| SG11201900744SA (en) | 2019-02-27 |
| US20200231693A1 (en) | 2020-07-23 |
| JP2019532025A (ja) | 2019-11-07 |
| IL264515A (en) | 2019-02-28 |
| EP3497126A1 (fr) | 2019-06-19 |
| CN109843916A (zh) | 2019-06-04 |
| US11359029B2 (en) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3383913A4 (fr) | Anticorps ciblant la protéine de type récepteur fc 5 et procédés d'utilisation | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| EP3410940A4 (fr) | Système d'imagerie médicale portable | |
| EP3390443A4 (fr) | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| EP3383412A4 (fr) | Anticorps spécifiques de la protéine pd-1 glycosylée et leurs procédés d'utilisation | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
| EP3448412A4 (fr) | Anticorps anti-vista humain et leur utilisation | |
| EP3645742A4 (fr) | Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation | |
| EP3240804A4 (fr) | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| EP3463062A4 (fr) | Systèmes et procédés d'analyse d'activité cérébrale et applications associées | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| EP3472200A4 (fr) | Anticorps anti-myostatine et leurs procédés d'utilisation | |
| MA40721A (fr) | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation | |
| EP3371572A4 (fr) | Systèmes et procédés d'imagerie optogénétique | |
| EP3383914A4 (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| EP2971141A4 (fr) | Systèmes et procédés pour l'analyse biologique | |
| MA43053A (fr) | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation | |
| MA55043A (fr) | Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20 | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation |